Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
REDWOOD CITY, Calif., Feb. 26, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Cowen and Company 36th Annual Healthcare Conference on Tuesday, March 8 at 10:00 am ET in Boston, Massachusetts.
A webcast of the presentation will be available on the Investors page of the Coherus website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit www.coherus.com.
CONTACT: Keith Vendola, M.D. Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 437-6239
